Categories: News | Published On: April 24, 2024 | Written by webadmin@biolojic.com |
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
